Blog | HemaCare

Stronger Together: HemaCare and Cellero Join Forces

Jan 12, 2021 10:06:00 AM / by Nancy Andon, MSc posted in Cell Therapy

0 Comments

HemaCare and Cellero are ringing in the New Year with the aspiration to be bigger and better!

Both cell supply companies are joining forces under the umbrella of Massachusetts-based Charles River Laboratories. The new coalition is a major part of Charles River’s strategy to expand its research and development capacity, by acquiring the expertise needed to bring cellular therapies all the way from sourcing starting materials through to commercialization.

Read More

Researchers Discover New Way to Empower T Cells' Anti-Tumor Activity

Jan 5, 2021 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, T Cells

0 Comments

Researchers have discovered that the use of antibody blocks TREM2 proteins can empower immune cells and destroy tumors, and eliminate completely in mouse models when they were combined with anti-PD-1 immunotherapy. 

Anti-cancer immunotherapy uses the body’s immune system to destroy tumor cells. Despite breakthroughs in this medical arena, a limited number of patients actually benefit from these therapies. A significant reason for the less-than-desirable responses is tumor cells’ ability to circumvent various T-cell immune mechanisms. Therefore, populations of resistant tumor cells hinder the effectiveness of current immunotherapeutic approaches in many patients.

Read More

T Cell Analysis Could Predict Type I Diabetes Immunotherapy Response

Dec 22, 2020 10:02:00 AM / by Stacy Matthews Branch, DVM, PhD posted in T Cells

0 Comments

Researchers at University College London found that the analysis of T Cells slowed the reduction in beta-cell functions, noting that some benefited more than others.

Type 1 diabetes (T1D) is an autoimmune disease that is T-cell–mediated. CD4+ T-helper cells and CD8+ cytotoxic T cells are thought to be involved in destroying insulin-producing β-cells. These immune cells and related subsets change in number and distribution throughout T1D pathogenesis. It is known that the level of T follicular helper cells (Tfh cells) in the peripheral blood of patients with T1D increase is higher compared to that in healthy patients.

Read More

Happy New Year! The Top Ten HemaCare Blogs of 2020

Dec 16, 2020 10:04:00 AM / by Nancy Andon, MSc posted in T Cells, NK Cells, Vaccine Research

0 Comments

Even as the New Year approaches, we are sure 2020 will never be forgotten!

The emergence of the COVID pandemic brought unprecedented challenges to all of us. At HemaCare we have been proud to see our cryopreserved leukopak products deliver timely aid to COVID-19 researchers by providing high-quality starting materials to a supply chain suddenly beset with disruptions. It comes as no surprise that several of the blogs in our “Top Ten” list are focused on COVID research carried out as scientists raced toward a vaccine.

Read More

Patients with Advanced Bladder Cancer May See Prolonged Survival with Immunotherapy

Dec 1, 2020 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy (Immunology)

0 Comments

Published in the medical journal New England Journal of Medicine, a study found the proven drug, avelumab, may help the survival rate of those diagnosed with bladder cancer. 

According to the American Cancer Society, the 2020 United States estimates for bladder cancer cases are approximately 81,400 for new cases and 17,980 deaths. However, bladder cancer is a worldwide concern being the 13th most common cancer. Platinum-based chemotherapy is the standard-of-care for advanced urothelial carcinoma. Nevertheless, progression-free and overall survival are minimal with chemotherapy.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts